Table 1.

Eligibility criteria for systematic literature review

Inclusion criteria	Exclusion criteria
Population	•Mild cognitive impairment or mild dementia due to AD (also referred to as early AD)	•Familial AD •Moderate to severe dementia due to AD •Any other dementia not caused by AD (e.g. vascular dementia, Lewy body dementia, mixed dementia, etc.)
Intervention	•No restrictions for prognostic studies •For predictive studies, approved or under late-stage development disease-modifying treatments:   ∘ Aducanumab   ∘ Donanemab   ∘ Gantenerumab   ∘ Lecanemab	•NA
Index prognostic factor	•No restrictions however examples may include: •Risk factors (age, sex, smoking, co-morbidities) •Symptoms (depression) •Global performance (MMSE, FAQ) •Biomarkers •Imaging biomarker •Genetic factors such as APOE	•NA
Comparator prognostic factors	•No restrictions	•NA
Outcomes*	•No restrictions for prognostic studies however examples may include:   ∘ Progression from one clinical state to another (MCI due to AD to AD)   ∘ Progression measured an outcome measure (MMSE, CDR-SB) •No restrictions for prediction studies however outcomes may typically be categorized as   ∘ Efficacy outcomes (as measured by MMSE, CDR-SB)   ∘ Safety outcomes (ARIA)	•NA
Timing	•No restrictions	•NA
Setting	•Predictive factors   ∘ Clinical setting (Randomized controlled trials) •Prognostic factors   ∘ Clinical and real-world setting (Prospective cohort studies, Retrospective cohort studies) •Systematic literature reviews	•Preclinical/animal studies •Cross-sectional studies •Case series •Case reports
Language	•English language publications only	•NA
Publication type	•Full publications only	•Conference abstracts
Publication date	•2011 onwards

AD, Alzheimer’s disease; APOE, apolipoprotein E; ARIA, amyloid related imaging abnormalities, CDR-SB, clinical dementia rating scale –sum of boxes; FAQ, functional activities questionnaire; HR, hazard ratio; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NA, not applicable; OR, odds ratio; RR, risk ratio. *Association of prognostic factors and progression reported as HR, RR, or OR.